Peptides
The Next GLP-1 Frontier: Oral Pills, Muscle Loss, and the Mind
As the GLP-1 class expands beyond weekly injections, three new studies sketch a more complicated risk-benefit map than the headline weight-loss numbers suggest.
obesity
Longevity
Weight, Teeth, and the Aging Mouth: What a New Review Says About Midlife and Beyond
A PRISMA-registered meta-analysis pooled 16 studies on adults 55+ and found a link between extra weight and worse oral health — especially gum disease. Here's what that actually means.
Peptides
The Next GLP-1s: Dual Fatty-Acid Conjugates and Combo Therapies Push Past Semaglutide
Two 2025 preclinical studies hint at where this class is heading — longer-acting molecules, beta-cell-protective stacks, and the first real challengers to semaglutide's throne.
Metabolic Health
Obesity as an Accelerator of Cardiovascular Aging — And Why Weight Loss May Buy You Time
A major European Heart Journal review reframes excess weight as a driver of the heart's biological aging itself. The implication: weight reduction may be less about preventing one bad day and more about extending healthy years.
Peptides
GLP-1s Beyond Diabetes: New Meta-Analysis Maps Cardiovascular and Gynecologic Frontiers
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.
Peptides
The Next Generation of GLP-1s: PYY Analogs, AI-Designed Molecules, and Weekly Insulin
Semaglutide and tirzepatide rewrote the metabolic playbook. The pipeline behind them is already bifurcating — and what arrives next will look less like one blockbuster shot and more like a stack.
Metabolic Health
Beyond GLP-1: Why the New Obesity Science Is About Your Fat, Not Your Scale
Three new reviews argue we've been measuring the wrong thing. The real target isn't weight — it's the adipose tissue quietly running your metabolism.
Metabolic Health
Obesity as an Immune Disease: Why Inflammation May Be the Missing Frame
A major new synthesis argues obesity is not just a metabolic condition but a fundamentally altered immunological state — reshaping how we think about GLP-1s, weight loss, and the body's defenses.
Metabolic Health
GLP-1 Reality Check: Doctors Underestimate the Upside, Patients Underuse the Drugs
New survey and claims data suggest a quiet mismatch in cardiometabolic care: physicians may be undercounting how much weight and risk these drugs move, while many eligible adults never start them.
Peptides
Beyond Semaglutide: The Next Wave of GLP-1 Combos and Dual Agonists
Phase III data on IcoSema and fresh SURMOUNT analyses of tirzepatide are rewriting what 'best-in-class' looks like for metabolic and obesity care.